Related Experiment Video

Updated: Jul 3, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Protein tyrosine phosphatase receptor-type O (PTPRO) is co-regulated by E2F1 and miR-17-92

Xin Xu1, Yan Hong, Chenfei Kong

  • 1Key Laboratory of Molecular Epigenetics of MOE, Institute of Genetics and Cytology, Northeast Normal University, Changchun 130024, China.

FEBS Letters
|July 23, 2008
PubMed

Insights

The protein tyrosine phosphatase receptor type O (PTPRO) gene, a tumor suppressor, is regulated by E2F1 and the miR-17-92 microRNA cluster. This co-regulation impacts PTPRO expression during the cell cycle.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Gene Regulation

Background:

  • PTPRO functions as a tumor suppressor and is frequently silenced by DNA hypermethylation in various cancers.
  • E2F1 is a transcription factor known to regulate genes involved in cell cycle progression and apoptosis.
  • MicroRNAs, such as the miR-17-92 cluster, are small non-coding RNAs that play crucial roles in gene silencing and cellular processes.

Purpose of the Study:

  • To investigate the regulatory relationship between PTPRO, E2F1, and the miR-17-92 microRNA cluster.
  • To elucidate the mechanisms by which E2F1 and miR-17-92 influence PTPRO gene expression.
  • To understand the role of this co-regulation in the context of the cell cycle.

Main Methods:

  • Analysis of PTPRO gene expression in cancer cell lines and primary tumors.
  • Investigating the binding of E2F1 to the PTPRO gene promoter.
  • Utilizing reporter assays to assess PTPRO promoter activity and 3'UTR activity during different cell cycle phases.
  • Synchronizing HeLa cells to study cell cycle-dependent gene expression.

Main Results:

  • PTPRO was identified as a direct target of E2F1.
  • The miR-17-92 microRNA cluster was also confirmed as a target of E2F1.
  • PTPRO mRNA levels increased during the S phase in synchronized HeLa cells.
  • In vitro studies showed high PTPRO promoter activity in early S phase and low PTPRO 3'UTR reporter activity in late S phase.

Conclusions:

  • PTPRO gene expression is co-regulated by both the transcription factor E2F1 and the miR-17-92 microRNA cluster.
  • This co-regulation mechanism contributes to the cell cycle-dependent modulation of PTPRO.
  • Understanding this regulatory network provides insights into PTPRO's role as a tumor suppressor.

More Related Videos

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes09:40

Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes

Published on: September 28, 2018

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.